Companies Akero Therapeutics, Inc.
Akero Therapeutics (AKRO): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Akero Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers80th pct.Of 16 peer CEOs
CEO pay, last three years
- $10,446,243FY2022
- $8,834,907FY2023
- $10,465,855FY2024
CEO total pay was $10,465,855 in fiscal 2024, up from $8,834,907 in fiscal 2023.
FY2024: salary $686,000 · bonus $0 · stock awards $2,879,155 · option awards $6,489,100
Executives and directors
Andrew Cheng · CEOJonathan Young · COOCatriona Yale · Chief Development OfficerScott Gangloff · CTOWilliam White · CFOGraham L. Walmsley · Independent DirectorJane Henderson · Independent DirectorJudy Chou · Independent DirectorMark T. Iwicki · Chair of the BoardSeth L. Harrison · Independent DirectorTomas Heyman · Independent DirectorYuan Xu · Independent Director
Frequently asked questions
Who was the highest-paid executive at Akero Therapeutics, Inc. in fiscal 2024?
As disclosed, Andrew Cheng (President and Chief Executive Officer) was the highest-paid executive at Akero Therapeutics, Inc. in fiscal 2024, with total compensation of $10,465,855.
How does Akero Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Andrew Cheng's total compensation ranked at the 80th percentile of Akero Therapeutics, Inc.'s disclosed peer group.
What is Akero Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Akero Therapeutics, Inc.'s CEO-to-median employee pay ratio was 15:1.
How did shareholders vote on Akero Therapeutics, Inc.'s executive compensation?
As disclosed, 98.06% of shareholders supported Akero Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Akero Therapeutics, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Akero Therapeutics, Inc. reported total board compensation of $413,750 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Cheng | $686,000 | $0 | $2,879,155 | $6,489,100 | $411,600 | $0 | $0 | $10,465,855 |
| President and Chief Executive Officer | ||||||||
| Scott Gangloff | 313,577 | 0 | 710,289 | 4,947,547 | 140,643 | 0 | 0 | 6,112,056 |
| Chief Technology Officer | ||||||||
| William White | 510,000 | 0 | 710,289 | 1,617,885 | 229,500 | 0 | 0 | 3,067,674 |
| Chief Financial Officer | ||||||||
| Catriona Yale | 494,000 | 0 | 710,289 | 1,617,885 | 222,300 | 0 | 0 | 3,044,474 |
| Chief Development Officer | ||||||||
| Jonathan Young | 490,000 | 0 | 710,289 | 1,617,885 | 220,500 | 0 | 0 | 3,038,674 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Andrew Cheng | $10,465,855 | $8,834,907 | $10,446,243 | ↑ +1,630,948 |
| Scott Gangloff | 6,112,056 | — | — | — |
| William White | 3,067,674 | 4,292,266 | — | ↓ −1,224,592 |
| Catriona Yale | 3,044,474 | 3,446,598 | 4,136,043 | ↓ −402,124 |
| Jonathan Young | 3,038,674 | 3,440,888 | 4,144,543 | ↓ −402,214 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is guided by our overarching philosophy of paying for demonstrable performance, designed to attract, motivate, and retain top-performing senior executives while aligning their interests with those of our stockholders to drive the creation of sustainable long-term value.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scott Gangloff | RSU | 2024-12-16 | — | — | 24,300 | — | $710,289 |
| Jonathan Young | RSU | 2024-12-16 | — | — | 24,300 | — | 710,289 |
| Andrew Cheng | RSU | 2024-12-16 | — | — | 98,500 | — | 2,879,155 |
| Catriona Yale | RSU | 2024-12-16 | — | — | 24,300 | — | 710,289 |
| Jonathan Young | OPTION | 2024-12-16 | — | — | 73,700 | — | 1,617,885 |
| William White | OPTION | 2024-12-16 | — | — | 73,700 | — | 1,617,885 |
| William White | RSU | 2024-12-16 | — | — | 24,300 | — | 710,289 |
| Scott Gangloff | OPTION | 2024-04-29 | — | — | 225,000 | — | 3,329,663 |
| Andrew Cheng | OPTION | 2024-12-16 | — | — | 295,600 | — | 6,489,100 |
| Catriona Yale | OPTION | 2024-12-16 | — | — | 73,700 | — | 1,617,885 |
| Scott Gangloff | OPTION | 2024-12-16 | — | — | 73,700 | — | 1,617,885 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scott Gangloff | $710,289 | $0 | $4,947,548 | 0.0% |
| Jonathan Young | 710,289 | 0 | 1,617,885 | 0.0% |
| Andrew Cheng | 2,879,155 | 0 | 6,489,100 | 0.0% |
| Catriona Yale | 710,289 | 0 | 1,617,885 | 0.0% |
| William White | 710,289 | 0 | 1,617,885 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| William White | RSU | 9,598 | — | $267,016 |
| Catriona Yale | RSU | 9,598 | — | 267,016 |
| Jonathan Young | RSU | 9,598 | — | 267,016 |
| William White | Option | 21,806 | 21.1 | — |
| Catriona Yale | Option | 21,806 | 21.1 | — |
| Jonathan Young | Option | 21,806 | 21.1 | — |
| William White | RSU | 24,300 | — | 676,026 |
| Scott Gangloff | RSU | 24,300 | — | 676,026 |
| Catriona Yale | RSU | 24,300 | — | 676,026 |
| Jonathan Young | RSU | 24,300 | — | 676,026 |
| William White | RSU | 24,373 | — | 678,057 |
| Catriona Yale | RSU | 24,373 | — | 678,057 |
| Jonathan Young | RSU | 24,373 | — | 678,057 |
| Andrew Cheng | RSU | 26,176 | — | 728,216 |
| William White | Option | 43,189 | 42.95 | — |
| Catriona Yale | Option | 43,189 | 42.95 | — |
| Jonathan Young | Option | 43,189 | 42.95 | — |
| William White | Option | 50,968 | 14.08 | — |
| Andrew Cheng | Option | 65,416 | 21.1 | — |
| Andrew Cheng | RSU | 68,656 | — | 1,910,010 |
| William White | Option | 73,700 | 29.23 | — |
| Scott Gangloff | Option | 73,700 | 29.23 | — |
| Catriona Yale | Option | 73,700 | 29.23 | — |
| Jonathan Young | Option | 73,700 | 29.23 | — |
| Andrew Cheng | RSU | 98,500 | — | 2,740,270 |
| William White | Option | 109,678 | 19.87 | — |
| Catriona Yale | Option | 109,678 | 19.87 | — |
| Jonathan Young | Option | 109,678 | 19.87 | — |
| Andrew Cheng | Option | 117,790 | 42.95 | — |
| Scott Gangloff | Option | 225,000 | 19.62 | — |
| Andrew Cheng | Option | 295,600 | 29.23 | — |
| Andrew Cheng | Option | 308,952 | 19.87 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark T. IwickiIndependent | $85,000 | $0 | $434,632 | $0 | $0 | $519,632 |
| Jane HendersonIndependent | 65,000 | 0 | 434,632 | 0 | 0 | 499,632 |
| Tomas HeymanIndependent | 60,000 | 0 | 434,632 | 0 | 0 | 494,632 |
| Graham L. WalmsleyIndependent · Audit · Compensation | 57,500 | 0 | 434,632 | 0 | 0 | 492,132 |
| Yuan XuIndependent | 52,500 | 0 | 434,632 | 0 | 0 | 487,132 |
| Judy ChouIndependent | 50,000 | 0 | 434,632 | 0 | 0 | 484,632 |
| Seth L. HarrisonIndependent | 43,750 | 0 | 434,632 | 0 | 0 | 478,382 |
| Andrew ChengEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $26,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $413,750 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $413,750 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Akero Therapeutics as a peer
Companies that benchmark against AKRO
12 companies name AKRO as a compensation peer
The list of companies that name AKRO as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MOR Morphic Holding, Inc.ANAB AnaptysBio, Inc.KURA Kura Oncology, Inc.MDGL Madrigal Pharmaceuticals, Inc.MNKD MannKind CorporationMIRM Mirum Pharmaceuticals, Inc.RAPT RAPT Therapeutics, Inc.REPL Replimune Group, Inc.TYRA Tyra Biosciences, Inc.VTYX Ventyx Biosciences, Inc.VKTX Viking Therapeutics, Inc.SNDX Syndax Pharmaceuticals, Inc.RGNX REGENXBIO Inc.TERN Terns Pharmaceuticals, Inc.ACRS Aclaris Therapeutics, Inc.CRNX Crinetics Pharmaceuticals, Inc.
Peer reciprocity
The companies Akero Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Therapeutics, Inc. | 2025 | Brian Lian | $672,000 | $17,756,817 | $2,468,016 | $373,000 | $21,269,833 |
| 2 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 3 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 4 | Akero Therapeutics, Inc. | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 5 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 6 | MannKind Corporation | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 7 | Terns Pharmaceuticals, Inc. | 2024 | Amy Burroughs | 563,701 | 807,750 | 6,476,968 | 375,000 | 8,240,502 |
| 8 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 9 | Rapt Therapeutics, Inc. | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 10 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 11 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 12 | Tyra Biosciences, Inc. | 2025 | Todd Harris | 658,000 | 0 | 4,568,037 | 325,710 | 5,566,997 |
| 13 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 14 | Regenxbio Inc. | 2025 | Curran Simpson | 665,510 | 777,448 | 2,350,302 | 387,327 | 4,200,712 |
| 15 | Aclaris Therapeutics, Inc. | 2025 | Neal Walker | 615,000 | 828,426 | 1,581,615 | 350,550 | 3,375,591 |
| 16 | Ventyx Biosciences, Inc. | 2024 | Raju Mohan | 621,920 | 0 | 303,800 | 342,045 | 1,283,015 |
| — | Morphic Holding, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Akero Therapeutics, Inc. | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Aclaris Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| MannKind Corporation | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| Mirum Pharmaceuticals, Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Morphic Holding, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Rapt Therapeutics, Inc. | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Regenxbio Inc. | 97% | Options 75 · RSU 25 | not disclosed | Willis Towers Watson |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Terns Pharmaceuticals, Inc. | 120% | not disclosed | No | Alpine Rewards |
| Tyra Biosciences, Inc. | not disclosed | Options 100 | not disclosed | Aon Rewards Solutions |
| Ventyx Biosciences, Inc. | not disclosed | not disclosed | not disclosed | AON/Radford |
| Viking Therapeutics, Inc. | not disclosed | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-03 | 60,698,263 | 1,199,541 | 162,539 | 98.06% | Passed |
| 2024 | 2024-04-10 | 52,835,974 | 2,548,327 | 283,303 | 95.4% | Passed |
| 2023 | 2023-06-23 | 35,932,802 | 1,204,824 | 8,274 | 96.76% | Passed |
| 2022 | 2022-06-02 | 20,723,978 | 129,384 | 9,327 | 99.38% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-03 | 98.06%a |
| 2024 | 2024-04-10 | 95.4%b |
| 2023 | 2023-06-23 | 96.76%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 3.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 3.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 15 : 1 |
|---|---|
| CEO total compensation | $8,834,907 |
| Median employee compensation | $577,062 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 12,466 | $44 | $550,611 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | A | 295 | 28 | 8,363 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 5,161 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-09-08 | — | 295 | — | — | 1 insider, 1 accrual row | ||
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 7,044 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | A | 5,161 | 6 | 32,845 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | A | 7,044 | 21 | 148,558 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 7,317 | 44 | 321,911 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-09-10 | — | 1,919 | — | — | 1 insider, 1 accrual row | ||
| Andrew Cheng | Director | 2025-09-10 | D | 13,022 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 158 | 45 | 7,050 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 22,525 | 43 | 968,440 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | A | 1,919 | 20 | 38,131 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | A | 13,022 | 6 | 82,872 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-11 | D | 553 | 43 | 23,790 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-09-11 | D | 659 | 43 | 28,350 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-11 | D | 1,796 | 43 | 77,264 | Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-09-11 | D | 659 | 43 | 28,350 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-09-11 | D | 586 | 43 | 25,210 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | D | 4,201 | 48 | 201,581 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | A | 12,500 | 21 | 263,750 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | D | 8,299 | 48 | 395,398 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | D | 11,463 | 46 | 527,447 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | D | 1,037 | 47 | 48,554 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | A | 12,500 | 28 | 354,375 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-08 | D | 52,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-08 | A | 52,212 | 1 | 32,110 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 23,832 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 23,832 | 20 | 475,925 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 13,000 | 25 | 327,600 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 13,000 | 26 | 342,160 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 15,000 | 8 | 121,950 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 26,000 | 23 | 598,520 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-10 | D | 30,000 | 54 | 1,619,340 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-10 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-10 | A | 30,000 | 20 | 596,100 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | D | 3,527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | D | 4,739 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | A | 4,739 | 21 | 99,993 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | A | 3,527 | 28 | 99,990 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-11-12 | D | 14,739 | 0 | 0 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-17 | D | 37,100 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-11-20 | D | 74,538 | 0 | 0 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | D | 4,739 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | D | 3,527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | D | 4,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | A | 4,739 | 21 | 99,993 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | A | 3,527 | 28 | 99,990 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | A | 4,284 | 21 | 90,350 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 3,527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 4,739 | 21 | 99,993 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 94,268 | 1 | 57,975 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 2,796 | 1 | 1,720 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 4,284 | 21 | 90,350 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 43,064 | 6 | 274,059 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 3,527 | 28 | 99,990 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 4,739 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 4,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 43,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 94,268 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 2,796 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-26 | D | 9,259 | 0 | 0 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 47,573 | — | — | Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 74,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 82,482 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 83,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 116,833 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 4,739 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 10,179 | — | — | Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 49,945 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 238,339 | — | — | Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 136,301 | — | — | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 277,075 | — | — | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 93,000 | — | — | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 233,252 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 204,616 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 73,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 17,784 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 21,263 | — | — | Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 5,088 | — | — | Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 74,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 47,573 | — | — | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 28,584 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 44,982 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 70,279 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 20,000 | — | — | Common, indirect | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 141,205 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 119,969 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 56,579 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 74,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 70,279 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 27,227 | — | — | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 234,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 23,809 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 374,985 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 292,179 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 3,527 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 52,785 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 33,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 131,205 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 43,810 | — | — | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 389 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 26,152 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 238,973 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 87,220 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 159,762 | — | — | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 1,200,000 | — | — | Common, indirect | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 11,493 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 70,587 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 29,073 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 20,000 | — | — | Common, indirect | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 20,000 | — | — | Common, indirect | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 152,616 | — | — | Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 11,797 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 84,904 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 48,679 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 11,096 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 382 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 26,832 | — | — | Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 64,182 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 3,059 | — | — | Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 29,073 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 76,227 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 4,739 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 24,745 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 70,279 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 18,964 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 3,527 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 47,573 | — | — | Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 148,063 | — | — | Common, indirect | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 165,289 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 200 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 12,466 | $44 | $550,611 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | A | 295 | 28 | 8,363 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 5,161 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | D | 7,044 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | A | 5,161 | 6 | 32,845 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-08 | A | 7,044 | 21 | 148,558 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 7,317 | 44 | 321,911 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 1,919 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 13,022 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 158 | 45 | 7,050 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | D | 22,525 | 43 | 968,440 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | A | 1,919 | 20 | 38,131 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-10 | A | 13,022 | 6 | 82,872 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-09-11 | D | 553 | 43 | 23,790 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-09-11 | D | 659 | 43 | 28,350 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-09-11 | D | 1,796 | 43 | 77,264 | Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-09-11 | D | 659 | 43 | 28,350 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-09-11 | D | 586 | 43 | 25,210 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | D | 4,201 | 48 | 201,581 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | A | 12,500 | 21 | 263,750 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-10-01 | D | 8,299 | 48 | 395,398 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | D | 11,463 | 46 | 527,447 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | D | 1,037 | 47 | 48,554 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-10-07 | A | 12,500 | 28 | 354,375 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-08 | D | 52,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-08 | A | 52,212 | 1 | 32,110 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 23,832 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 23,832 | 20 | 475,925 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 13,000 | 25 | 327,600 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 13,000 | 26 | 342,160 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 15,000 | 8 | 121,950 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | A | 26,000 | 23 | 598,520 | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 13,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-10-08 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-10 | D | 30,000 | 54 | 1,619,340 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-10 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-10-10 | A | 30,000 | 20 | 596,100 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | D | 3,527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | D | 4,739 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | A | 4,739 | 21 | 99,993 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-11-04 | A | 3,527 | 28 | 99,990 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-11-12 | D | 14,739 | 0 | 0 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-17 | D | 37,100 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-11-20 | D | 74,538 | 0 | 0 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | D | 4,739 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | D | 3,527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | D | 4,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | A | 4,739 | 21 | 99,993 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | A | 3,527 | 28 | 99,990 | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-24 | A | 4,284 | 21 | 90,350 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 3,527 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 4,739 | 21 | 99,993 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 94,268 | 1 | 57,975 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 2,796 | 1 | 1,720 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 4,284 | 21 | 90,350 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 43,064 | 6 | 274,059 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | A | 3,527 | 28 | 99,990 | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 4,739 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 4,284 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 43,064 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 94,268 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-11-25 | D | 2,796 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-11-26 | D | 9,259 | 0 | 0 | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 47,573 | — | — | Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 74,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 82,482 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 83,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 116,833 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 4,739 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 10,179 | — | — | Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 49,945 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 238,339 | — | — | Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 136,301 | — | — | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 277,075 | — | — | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 93,000 | — | — | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 233,252 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 204,616 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 73,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 17,784 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 21,263 | — | — | Common | Form 4 ↗ |
| Scott Gangloff | Chief Technology Officer | 2025-12-09 | D | 5,088 | — | — | Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 74,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 47,573 | — | — | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 28,584 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 44,982 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 70,279 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 20,000 | — | — | Common, indirect | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 141,205 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 119,969 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 56,579 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 74,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 70,279 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chou Judy | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 27,227 | — | — | Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 234,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 23,809 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 374,985 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 292,179 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 3,527 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 52,785 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 33,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 131,205 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Catriona Yale | Chief Development Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 43,810 | — | — | Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 389 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 26,152 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Rolph | Chief Scientific Officer | 2025-12-09 | D | 5,032 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 238,973 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 87,220 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 159,762 | — | — | Common | Form 4 ↗ |
| G. Walmsley Graham | Director | 2025-12-09 | D | 1,200,000 | — | — | Common, indirect | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 11,493 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 70,587 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 29,073 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 84,051 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 2,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 20,000 | — | — | Common, indirect | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 20,000 | — | — | Common, indirect | Form 4 ↗ |
| Jonathan Young | Chief Operating Officer | 2025-12-09 | D | 152,616 | — | — | Common | Form 4 ↗ |
| Jane Henderson | Director | 2025-12-09 | D | 11,797 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 84,904 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 48,679 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 11,096 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 382 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 26,832 | — | — | Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 64,182 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patrick Lamy | See Remarks | 2025-12-09 | D | 3,059 | — | — | Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 29,073 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 29,074 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 76,227 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 4,739 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 24,745 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 70,279 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 18,964 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 3,527 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 3,421 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William White | Chief Financial Officer | 2025-12-09 | D | 47,573 | — | — | Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark T. Iwicki | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 9,398 | — | — | Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 148,063 | — | — | Common, indirect | Form 4 ↗ |
| Andrew Cheng | Director | 2025-12-09 | D | 165,289 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Seth L. Harrison | Director | 2025-12-09 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tomas Heyman | Director | 2025-12-09 | D | 13,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Sources (248 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Andrew Cheng. DEF 14A, filed 2025-04-28. Section “EXECUTIVE COMPENSATION TABLES” · page 24. As printed: 10,465,855. View filing ↗
- Section 01, Scott Gangloff. DEF 14A, filed 2025-04-28. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 6,112,056. View filing ↗
- Section 01, William White. DEF 14A, filed 2025-04-28. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 3,067,674. View filing ↗
- Section 01, Catriona Yale. DEF 14A, filed 2025-04-28. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 3,044,474. View filing ↗
- Section 01, Jonathan Young. DEF 14A, filed 2025-04-28. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 3,038,674. View filing ↗
- Section 03, Scott Gangloff RSU. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Young RSU. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Cheng RSU. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Catriona Yale RSU. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Young OPTION. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, William White OPTION. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, William White RSU. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Gangloff OPTION. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Cheng OPTION. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Catriona Yale OPTION. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Scott Gangloff OPTION. DEF 14A, filed 2025-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2024-04-26. Section “CEO Pay Ratio”. As printed: 15 : 1. View filing ↗
- Section 08, Mark T. Iwicki. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 519,632. View filing ↗
- Section 08, Jane Henderson. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 499,632. View filing ↗
- Section 08, Tomas Heyman. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 494,632. View filing ↗
- Section 08, Graham L. Walmsley. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 492,132. View filing ↗
- Section 08, Yuan Xu. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 487,132. View filing ↗
- Section 08, Judy Chou. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 484,632. View filing ↗
- Section 08, Seth L. Harrison. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 478,382. View filing ↗
- Section 08, Andrew Cheng. DEF 14A, filed 2025-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-08. Form 4, filed 2025-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-10. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-09-11. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-09-11. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-09-11. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-09-11. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-09-11. Form 4, filed 2025-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-10-01. Form 4, filed 2025-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-10-01. Form 4, filed 2025-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-10-01. Form 4, filed 2025-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-10-01. Form 4, filed 2025-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-10-07. Form 4, filed 2025-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-10-07. Form 4, filed 2025-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-10-07. Form 4, filed 2025-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-10-07. Form 4, filed 2025-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-10-08. Form 4, filed 2025-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-10-08. Form 4, filed 2025-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-10-08. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-10-10. Form 4, filed 2025-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-10-10. Form 4, filed 2025-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-10-10. Form 4, filed 2025-10-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-11-04. Form 4, filed 2025-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-11-04. Form 4, filed 2025-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-11-04. Form 4, filed 2025-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-11-04. Form 4, filed 2025-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-11-12. Form 4, filed 2025-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-17. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-11-20. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-24. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-24. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-24. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-24. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-24. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-24. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-11-25. Form 4, filed 2025-11-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-11-26. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chou Judy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Gangloff 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Gangloff 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Gangloff 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Gangloff 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Gangloff 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tomas Heyman 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tomas Heyman 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tomas Heyman 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chou Judy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chou Judy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chou Judy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chou Judy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catriona Yale 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Rolph 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, G. Walmsley Graham 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Young 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Henderson 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Lamy 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tomas Heyman 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William White 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark T. Iwicki 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seth L. Harrison 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tomas Heyman 2025-12-09. Form 4, filed 2025-12-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-04. Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 60,698,263). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 95.4% (votes for as printed: 52,835,974). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-26. Item 5.07 · say-on-pay result. As reported: 96.76% (votes for as printed: 35,932,802). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 413,750 + equity 0 + all other 0 = 413,750, summed across the director compensation table rows.
- Viking Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Viking Therapeutics, Inc.'s own proxy. As printed: 21,269,833. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- Crinetics Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Akero Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics, Inc.'s own proxy. As printed: 10,465,855. View filing ↗
- Mirum Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. View filing ↗
- MannKind Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in MannKind Corporation's own proxy. As printed: 9,300,485. View filing ↗
- Terns Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Terns Pharmaceuticals, Inc.'s own proxy. As printed: 8,240,502. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Rapt Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics, Inc.'s own proxy. As printed: 6,979,539. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- Replimune Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. View filing ↗
- Tyra Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Tyra Biosciences, Inc.'s own proxy. As printed: 5,566,997. View filing ↗
- Kura Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- Regenxbio Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Regenxbio Inc.'s own proxy. As printed: 4,200,712. View filing ↗
- Aclaris Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Aclaris Therapeutics, Inc.'s own proxy. As printed: 3,375,591. View filing ↗
- Ventyx Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Ventyx Biosciences, Inc.'s own proxy. As printed: 1,283,015. View filing ↗
- Section 10a, Viking Therapeutics, Inc. reciprocity. DEF 14A. Viking Therapeutics, Inc. names Akero Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗